Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

Á÷Àå¾Ï¿¡¼­ ¼ö¼ú´Üµ¶ ¶Ç´Â ¼ö¼úÈÄ ¹æ»ç¼±Ä¡·á -»ýÁ¸À², °ñ¹ÝÁ¾¾çÁ¦¾îÀ², ¿¹ÈÄÀÎÀÚ¸¦ Áß½ÉÀ¸·Î- Surgery Alone or Postoperative Adjuvant Radiotherapy in Rectal Cancer -With Respect to Survival, Pelvic Control, Prognostic Factor-

´ëÇѹæ»ç¼±Á¾¾çÇÐȸÁö 2001³â 19±Ç 4È£ p.327 ~ 334
¼Ò¼Ó »ó¼¼Á¤º¸
³²ÅñÙ/Taek Keun Nam ¾È¼ºÀÚ/³ªº´½Ä/Sung Ja Ahn/Byung Sik Nah

Abstract

¸ñÀû: Á÷Àå¾Ï¿¡ ´ëÇÑ ¼ö¼ú ´Üµ¶ ¶Ç´Â ¼ö¼úÈÄ ¹æ»ç¼±Ä¡·á¸¦ ¹ÞÀº ȯÀÚ¸¦ ´ë»óÀ¸·Î °ñ¹ÝÁ¾¾çÁ¦¾îÀ²°ú »ýÁ¸À², ÇÕº´Áõ ¹ß»ý·ü, ¿¹ÈÄÀÎÀÚ µîÀ» ÈÄÇâÀûÀ¸·Î ºñ±³ ºÐ¼®ÇÏ¿© ¹æ»ç¼±Ä¡·áÀÇ ¿ªÇÒÀ» Æò°¡ÇÑ´Ù. ´ë»ó ¹× ¹æ¹ý: 1982³â 2¿ùºÎÅÍ 1996³â 12¿ù±îÁö ÃÑ
212¸íÀÇ È¯ÀÚ°¡ modified Astler-Coller º´±â B2¡­C3 Á÷Àå¾ÏÀ¸·Î Áø´ÜµÇ¾î ±ÙÄ¡Àû¸ñÀûÀÇ ¼ö¼ú´Üµ¶ ¶Ç´Â ¼ö¼úÈÄ ¹æ»ç¼±Ä¡·á¸¦ ½ÃÇàÇÏ¿´´Âµ¥, ÀÌÁß 39.6 Gy ¹Ì¸¸ÀÇ ¹æ»ç¼±Ä¡·á¸¦ ¹ÞÀº 18¸íÀ» Á¦¿ÜÇÑ 194¸íÀ» ´ë»óÀ¸·Î ÇÏ¿´´Ù. 104¸íÀº ¼ö¼úÈÄ ¹æ»ç¼±Ä¡·á¸¦ ¹Þ¾Ò°í
90¸íÀº
¼ö¼ú ´Üµ¶À» ½ÃÇàÇÏ¿´´Ù. ¹æ»ç¼±Ä¡·á´Â ÀÏÀÏ Á¶»ç·® 1.8¡­2.0 Gy·Î ÁÖ 5ȸ¾¿ Àü°ñ¹Ý°­¿¡ 39.6¡­55.8 Gy (Æò±Õ : 49.9 Gy)¸¦ Á¶»çÇÏ¿´°í ÇÊ¿ä½Ã ¿ø¹ß Á¾¾ç ÀýÁ¦ºÎÀ§¿¡ 5.4¡­10 Gy¸¦ Ãß°¡ Á¶»çÇÏ¿´´Ù. »ýÁ¸À²°ú °ñ¹ÝÁ¾¾çÁ¦¾îÀ²ÀÇ »êÃâÀº Kaplan-Meier¹æ¹ýÀ¸·Î, À̵éÀÇ
Åë°èÀû
À¯ÀǼº°ËÁõÀº Log-rank test·Î ÇÏ¿´´Ù. ´Ù¿äÀÎ ºÐ¼®Àº Cox proportional hazards modelÀ» ÀÌ¿ëÇÏ¿´´Ù. °á°ú: Àüü ȯÀÚÀÇ 5³â »ýÁ¸À² ¹× ¹«º´ »ýÁ¸À²Àº °¢°¢ 53%, 49%À̾ú´Ù. ¼ö¼ú´Üµ¶±º°ú ¹æ»ç¼±Ä¡·á Ãß°¡±ºÀÇ 5³â »ýÁ¸À²Àº °¢°¢ 63%¿Í 45%·Î À¯ÀÇÇÑ Â÷À̸¦
º¸¿´´Ù(p=0.03). ±×·¯³ª ÀÌ·¯ÇÑ Â÷ÀÌ´Â ¹æ»ç¼±Ä¡·á Ãß°¡±º¿¡¼­ ÁøÇàµÈ º´±âÀÇ È¯ÀÚ°¡ ´õ ¸¹ÀÌ ºÐÆ÷ÇÔ¿¡ ±âÀÎÇÑ °ÍÀ¸·Î »ý°¢µÇ¾ú´Ù(p<0.05 by ¥ö2-test). ¼ö¼ú´Üµ¶±º°ú ¹æ»ç¼±Ä¡·á Ãß°¡±ºÀÇ 5³â»ýÁ¸À²Àº º´±â B2£«3, C1, C2£«3 ±º¿¡¼­ °¢°¢ 68% ´ë 55%
(p=0.09),
100% ´ë 100%, 40% ´ë 33% (p=0.71)·Î µÎ ±º°£ÀÇ À¯ÀÇÇÑ Â÷ÀÌ´Â ¾ø¾ú´Ù. À§ÀÇ º´±âº° 5³â ¹«º´»ýÁ¸À²Àº °¢°¢ 65% ´ë 49% (p=0.14), 100% ´ë 100%, 33% ´ë 31% (p=0.46)·Î ¿ª½Ã À¯ÀÇÇÑ Â÷ÀÌ´Â ¾ø¾ú´Ù. Àüü ȯÀÚÀÇ 5³â °ñ¹ÝÁ¾¾çÁ¦¾îÀ²Àº 72.5%À̾ú´Ù. ¼ö¼ú´Üµ¶±º°ú
¹æ»ç¼±Ä¡·á Ãß°¡±ºÀÇ °ñ¹ÝÁ¾¾çÁ¦¾îÀ²Àº °¢°¢ 71%, 74%À̾ú´Ù(p=0.41). º´±â B2£«3, C1, C2£«3±º¿¡¼­ ¼ö¼ú´Üµ¶±º°ú ¹æ»ç¼±Ä¡·á Ãß°¡±ºÀÇ °ñ¹ÝÁ¾¾çÁ¦¾îÀ²Àº °¢°¢ 79% ´ë 75% (p=0.88), 100% ´ë 100%, 44% ´ë 68% (p=0.01)À̾ú´Ù. Àüü ȯÀÚ¸¦ ´ë»óÀ¸·Î ´Ù¿äÀÎ ºÐ¼®À»
½ÃÇàÇÑ
°á°ú »ýÁ¸À²°ú ¹«º´»ýÁ¸À²¿¡ º´±â¸¸ÀÌ À¯ÀÇÇÏ¿´°í µÎ Ä¡·á ±º¿¡¼­µµ ¿ª½Ã º´±â°¡ À¯ÀÇÇÑ ÀÎÀÚ·Î ³ªÅ¸³µ´Ù. ÀüüȯÀÚ¿¡¼­ °ñ¹ÝÁ¾¾çÁ¦¾îÀ²¿¡ À¯ÀÇÇÑ ¿¹ÈÄÀÎÀÚ·Î ´Ù¿äÀκм®À» ½ÃÇàÇÑ °á°ú º´±â¿Í ¼ö¼ú¹æ¹ýÀÌ À¯ÀÇÇÏ¿´´Ù. ¼ö¼ú´Üµ¶±º¿¡¼­´Â º´±â¸¸ÀÌ À¯ÀÇÇÏ¿´°í
¹æ»ç¼±Ä¡·á
Ãß°¡±º¿¡¼­´Â ¼ö¼ú¹æ¹ý¸¸ÀÌ À¯ÀÇÇÏ¿© º¹ºÎȸÀ½ÀýÁ¦¼ú±ºÀÇ °ñ¹ÝÁ¾¾çÀç¹ß·üÀÌ ³ô¾Ò´Ù. °á·Ð: º» ÈÄÇâÀû ¿¬±¸¿¡¼­ ¼ö¼ú ÈÄ º¸Á¶Àû ¹æ»ç¼±Ä¡·á¸¦ ½ÃÇàÇÏ¿© ¼ö¼ú´Üµ¶±º¿¡ ºñÇØ º´±â C2£«3±º¿¡¼­ °ñ¹ÝÁ¾¾çÁ¦¾îÀ²ÀÌ Çâ»óµÇ¾úÀ½À» ¾Ë ¼ö ÀÖ¾ú´Ù. ±×·¯³ª º´±â
B2ÀÌ»óÀÇ
¸ðµç
ȯÀÚ¿¡¼­ °ñ¹ÝÁ¾¾çÁ¦¾îÀ² »Ó¸¸ ¾Æ´Ï¶ó »ýÁ¸À²ÀÇ Çâ»óÀ» °¡Á®¿À±â À§Çؼ­´Â ÃÖ±Ù È¿¿ë¼ºÀÌ ³Î¸® ÀÔÁõµÈ ¿¬¼ÓÁÖ»ç¹ýÀÇ 5-FU¸¦ Æ÷ÇÔÇÑ µ¿½ÃÀû Ç×ÇÔÈ­Çйæ»ç¼± º´¿ë¿ä¹ýÀÌ ½ÃµµµÇ¾î¾ß ÇÒ °ÍÀ¸·Î »ý°¢µÈ´Ù.

Purpose: To find out the role of postoperative adjuvant radiotherapy in the treatment of rectal cancer by comparing survival, pelvic control, complication rate, and any prognostic factor between surgery alone and postoperative radiotherapy
group.
Materials and methods: From Feb. 1982 to Dec. 1996 total 212 patients were treated by radical surgery with or without postoperative radiotherapy due to rectal carcinoma of modified Astler-Coller stage B2¡­C3. Of them, 18 patients had
incomplete
radiotherapy and so the remaining 194 patients were the database analyzed in this study. One hundred four patients received postoperative radiotherapy and the other 90 patients had surgery only. Radiotherapy was performed in the range of
39.6¡­55.8
Gy
(mean: 49.9 Gy) to the whole pelvis and if necessary, tumor bed was boosted by 5.4¡­10 Gy. Both survival and pelvic control rates were calculated by Kaplan-Meier method and their statistical significance was tested by Log-rank test. Multivariate
analysis was performed by Cox proportional hazards model. Results: 5-year actuarial survival rate (5YSR) and 5-year disease-free survival rate (5YDFSR) of entire patients were 53% and 49%, respectively. 5YSRs of surgery alone group and
adjuvant
radiotherapy group were 63% vs 45%, respectively (p=0.03). This difference is thought to reflect uneven distribution of stages between two treatment groups (p<0.05 by ¥ö2-test) with more advanced disease patients in adjuvant
radiotherapy
group. 5YSRs of surgery alone vs adjuvant radiotherapy group in MAC B2£«3, C1, C2£«3 were 68% vs 55% (p=0.09), 100% vs 100%, 40% vs 33% (p=0.71), respectively. 5YDFSRs of surgery alone vs adjuvant radiotherapy group in above three stages were 65%
vs 49%
(p=0.14), 100% vs 100%, 33% vs 31% (p=0.46), respectively. 5-year pelvic control rate (5YPCR) of entire patients was 72.5%. 5YPCRs of surgery alone and adjuvant radiotherapy group were 71% vs 74%, respectively (p=0.41). 5YPCRs of surgery alone vs
adjuvant radiotherapy group in B2£«3, C1, C2£«3 were 79% vs 75% (p=0.88), 100% vs 100%, 44% vs 68% (p=0.01), respectively. Multivariate analysis showed that only stage was significant factor affecting overall and disease-free survival in entire
patients
and also in both treatment groups. In view of pelvic control, stage and operation type were significant in entire patients and only stage in surgery alone group but in adjuvant radiotherapy group, operation type instead of stage was the only
significant
factor in multivariate analysis as a negative prognostic factor in abdominoperineal resection cases. Conclusion: Our retrospective study showed that postoperative adjuvant radiotherapy could improve the pelvic control in MAC C2£«3 group.
To
improve both pelvic control and survival in all patients with MAC B2 or more, other treatment modality such as concurrent continuous infusion of 5-FU, which is the most standard agent, along with radiotherapy should be considered.

Å°¿öµå

Á÷Àå¾Ï; ¼ö¼úÈÄ ¹æ»ç¼±Ä¡·á; °ñ¹ÝÁ¾¾çÁ¦¾î; Rectal cancer; Postoperative radiotherapy; Pelvic control;

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

   

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed
KAMS